GRAIL Galleri Wins FDA Panel Support for Cancer Test

Sunnyvale, California, September 23, 2026

Galleri Uses Blood-Based Cancer Detection Technology

Galleri is a prescription-only, blood-based in vitro diagnostic test designed to detect cancer-specific methylation patterns in cell-free DNA collected from peripheral blood. The technology is intended to identify signals associated with multiple cancer types, including cancers for which there are currently no recommended routine screening tests. When a cancer signal is detected, Galleri is also designed to predict the Cancer Signal Origin (CSO), helping healthcare professionals determine where the detected signal may have originated and guide subsequent diagnostic evaluation. The test is intended to be used in addition to, and not as a replacement for, guideline-recommended cancer screenings. This distinction is important because existing screening programs for cancers such as breast, cervical, colorectal, and lung cancer remain part of standard preventive care where applicable. Galleri is being developed as an additional screening approach intended to broaden the number of cancers that can potentially be detected before symptoms appear.

Clinical Evidence Supports FDA Regulatory Review

GRAIL’s PMA submission was filed with the FDA on January 29, 2026, and the company has been developing Galleri through a large clinical research program involving hundreds of thousands of participants across multiple studies. The FDA’s review included data from PATHFINDER 2 and the NHS-Galleri trial, including prospective and randomized study data relevant to the intended-use population. In the company’s announcement, GRAIL reported that Galleri detected approximately four to seven times more cancers than standard-of-care screening alone in clinical studies, with many cancers detected at earlier stages. The company also reported a low false-positive rate and high accuracy for predicting the likely origin of a detected cancer signal. These company-reported findings formed part of the broader evidence package considered during the regulatory review. However, clinical evidence has also identified important questions surrounding the effectiveness of multi-cancer screening. Reporting on the advisory committee meeting noted that the NHS-Galleri randomized trial did not demonstrate a reduction in stage III/IV cancer incidence after three annual screening rounds, an outcome that remains relevant to understanding the technology’s clinical utility.

FDA Final Decision Still Pending

The advisory committee’s September 23 vote represents expert advice to the FDA rather than a final marketing authorization. The agency considers advisory committee recommendations as part of its regulatory decision-making process but is not legally required to follow the committee’s vote. GRAIL stated that it will continue working with the FDA as the agency completes its review of the Galleri PMA application. Galleri previously received FDA Breakthrough Device designation in 2018, reflecting the agency’s recognition of the technology’s potential to address an unmet need. If ultimately approved, Galleri would represent a significant regulatory development for multi-cancer early detection diagnostics, an emerging field that combines next-generation sequencing, molecular biology, artificial intelligence, and large-scale clinical research.

For cGxP.wire readers, the development highlights the growing role of blood-based diagnostics and molecular testing in cancer screening. The next regulatory milestone will be the FDA’s final decision on GRAIL’s PMA application. Until that decision is issued, Galleri’s advisory committee recommendation should be distinguished from final FDA approval.

Source: GRAIL press release